Can the Vaginal Microbiome Affect Fertility? What We Know, What Is Emerging and What We Still Cannot Promise

The vaginal microbiome is one of the most accessible markers of the reproductive microbial environment. It matters, but it cannot be interpreted as a simple Lactobacillus score or as the whole explanation for a complex fertility case.

At present, we still have limited data. We are learning to distinguish between the vaginal microbiome, the uterine or endometrial microbiome, and lower-biomass microbial communities associated with the ovaries, follicular fluid and other parts of the reproductive tract. They are connected, but they are not interchangeable.

Why the vaginal microbiome matters

A vaginal sample is the easiest part of the reproductive microbial environment to test. It gives us a practical marker of local acidity, epithelial protection and inflammatory activity. This is why vaginal microbiome testing is a routine part of my fertility assessments and often becomes the starting point for the wider investigation.

In more complex fertility and IVF cases, the vaginal result may not be enough. The vaginal and uterine microbiomes answer different questions, and there are cases in which both need to be investigated. I will cover the uterine microbiome separately, because it requires its own discussion of sampling, interpretation and clinical relevance.

IVF populations should not be treated as a simple comparison group. If a person already needs IVF, the clinical picture is usually complex: age, hormonal stimulation, previous treatment, implantation history, inflammation, metabolic health and antimicrobial exposure may all sit behind the microbiome result.

There is more than one vaginal microbial community

The vaginal microbiome is a biological community, not a list of isolated organisms. In practical terms, I look at at least four broad patterns:

• communities dominated by Lactobacillus crispatus;
• communities dominated by other Lactobacillus species, including L. iners, L. gasseri or L. jensenii;
• Bifidobacterium-dominant communities, reported in roughly 5% of women but seen more often in my practice because I work with complex cases;
• and non-Lactobacillus-dominant or more diverse communities, which may include Prevotella, Gardnerella, Streptococcus and other organisms.

These patterns are not biologically equivalent. They can differ in stability, acidity, inflammatory signalling and how they respond to treatment. Each community type needs its own interpretation and its own support plan. A report should never be reduced to “Lactobacillus present” or “Lactobacillus absent”.

A Bifidobacterium-dominant community is not automatically abnormal simply because Lactobacillus is not the leading genus. A Prevotella-dominant or otherwise inflammatory pattern, however, still needs proper assessment in the context of symptoms, fertility history and the next reproductive decision.

An abnormal result needs more than one prescription

If a test shows that the community is out of balance, one course of antibiotics is never the whole answer. Antibiotics may be clinically necessary and must be prescribed by a qualified medical professional, but the vaginal microbiome is a complex ecological community. Treatment needs a plan for reassessment, restoration and the factors that may be preventing the community from becoming stable.

Those factors may include gut dysbiosis, metabolic syndrome, a polycystic-ovary pattern, repeated antimicrobial exposure, hormonal changes, confirmed environmental mycotoxin exposure or infections within the wider TORCH picture—clinical shorthand for Toxoplasma, Other infections, Rubella, Cytomegalovirus, Herpes virus and Varicella-zoster virus (shingles). None of these should be assumed from a vaginal result alone. They become relevant when the history and other evidence point in that direction.

Support may need to continue into pregnancy

For some women whose vaginal community does not remain Lactobacillus-dominant without support, the plan may need to continue through preparation for pregnancy and during pregnancy. The purpose is to maintain a protective microbial environment rather than repeatedly wait for symptoms or another abnormal result.

This deserves particular attention towards the end of the second trimester, when recolonisation by Group B Streptococcus and other organisms may become part of the clinical picture in complex pregnancy loss or preterm-birth risk. Microbiome testing does not replace routine antenatal screening, and any treatment or ongoing support during pregnancy must be agreed with the woman’s obstetric, midwifery or medical team.

The assessment I recommend

I recommend starting with the full fertility timeline and then deciding what the vaginal result needs to answer. The assessment may include:

• symptoms, recurrent BV, urinary history and previous treatment;
• the species-level pattern, including detailed fungal analysis; not every test can provide this level of fungal detail, but sometimes it offers one of the biggest clues;
• whether the result is stable after treatment or changes again;
• gut, metabolic, hormonal, immune and environmental context;
• testing the partner in every case; the Male Fertility and seminal microbiome section explains why the male side cannot be left outside the investigation;
• whether a uterine sample is needed in addition to the vaginal sample;
• and what needs to be resolved before conception, embryo transfer or pregnancy.

Before booking, you may want to familiarise yourself with my methodology. If you have a vaginal microbiome result, recurrent BV, previous IVF treatment or an unexplained fertility history, you can book an Introductory Fertility Review. I will review the result as part of the complete clinical picture and propose a staged assessment plan.

This article is educational and does not replace medical advice, diagnosis or treatment. Diagnosis and any prescribed treatment should be provided by a qualified medical professional.